Meta: This report covers a not yet recruiting pediatric trial evaluating voice outcomes after adenoidectomy and adenotonsillectomy and its regulatory and clinical implications for families and clinicians.
In ClinicalTrials.gov a Turkish hospital sponsor has listed a study focused on adenoid hypertrophy and tonsillar hypertrophy with reports of voice disorders in children. The record identifies the conditions Adenoid Hypertrophy; Tonsillar Hypertrophy; Voice Disorders in Children and lists Gaziosmanpasa Research and Education Hospital as sponsor. The trial status is Not yet recruiting and the public record provides a direct link to the trial entry. The link available to stakeholders is ClinicalTrials.gov NCT07399041.
What regulatory changes accompany pediatric airway surgery outcome studies?
Regulatory frameworks for medical devices and related procedures require clear statements of intended use, performance expectations and safety measures. In MDR Annex XIV language such data support clinical evaluation plans and risk management. Although this study is described as a clinical evaluation of a surgical procedure rather than a device the registration demonstrates how sponsors describe intended population scope and oversight. The ClinicalTrials.gov entry confirms the not yet recruiting status and lists Gaziosmanpasa Research and Education Hospital as sponsor. The direct link to the record is included above in the opening block.
In practice such trial records help regulators and industry assess risk categories database reporting and post study safety considerations. The entry indicates the target conditions Adenoid Hypertrophy Tonsillar Hypertrophy and Voice Disorders in Children which is relevant to pediatric ENT oversight. Stakeholders should review the record for inclusion criteria monitoring plans and ethical oversight details. For researchers and families these disclosures provide transparency about the study design and expected timeline.
Who should care about these findings and why?
Clinicians managing pediatric airway problems and speech specialists will use voice outcome data to guide treatment choices and to inform families about potential benefits and risks of airway surgery. Regulators and manufacturers of related devices or tools will look to such data for context on performance and safety considerations in real world settings. Families may seek clarity about how voice functions could change after therapy and whether follow up is planned. The shared record and its update cadence enhance accountability and enable independent review.
While the current entry does not provide results it signals regulatory interest in patient centered outcomes and aligns with the broader push toward transparent trial documentation for pediatric procedures. The sponsor has published a public link to the trial record so investigators can assess compatibility with local ethical standards and data protections. For readers seeking deeper context consider visiting related coverage on pediatric ENT outcomes and regulatory perspectives linked in this article.
What are the conditions scope and sponsor details of the trial?
The study lists Adenoid Hypertrophy and Tonsillar Hypertrophy as conditions of interest and notes Voice Disorders in Children as a related complication or outcome area. The sponsor is Gaziosmanpasa Research and Education Hospital, and the status is Not yet recruiting.
The record references a Turkish health care setting and demonstrates how sponsors describe study aims and oversight in public registries. The information is intended to aid clinicians researchers and regulatory professionals in evaluating feasibility and potential impact on standard care. The direct ClinicalTrials.gov link again provides access to official documentation and any updates as the trial progresses.
What outcomes are tracked and how is safety ensured?
The core focus is the effect of adenoidectomy and adenotonsillectomy on voice in children. Specific outcomes are not detailed in the summary but would typically include measures of voice quality and functional status alongside safety monitoring for the pediatric population. Regulatory practice under MDR Annex XIV requires a clear clinical evaluation plan describing how data will be collected analyzed and used to support ongoing safety and performance decisions.
Ethical oversight would ordinarily include committee review and ongoing safety monitoring as part of any pediatric trial protocol. Readers should monitor the ClinicalTrials.gov record for updates including eligibility criteria and enrollment status. The public record provides a transparent view of how such a trial is designed and supervised.
FAQ
- 1. What is the purpose of the trial NCT07399041?
The trial aims to observe how adenoidectomy and adenotonsillectomy influence voice outcomes in children with airway and voice concerns while ensuring proper governance and safety oversight.
- 2. Who is sponsoring the trial?
Gaziosmanpasa Research and Education Hospital is listed as sponsor in the ClinicalTrials.gov record.
- 3. What is the current recruitment status?
The record shows Not yet recruiting; no study results are available yet.
- 4. Where can I review the official trial record?
The official record is available at ClinicalTrials.gov with the entry NCT07399041 and is linked in the opening block of this article.
Conclusion
This entry highlights how a pediatric airway surgery trial is registered and communicated to the public within a regulatory framework. The emphasis on voice outcomes adds a patient centered dimension to the usual safety and performance considerations. Stakeholders including clinicians families and regulatory professionals should track updates on recruitment status and any posted results through the official registry link. The case demonstrates the ongoing integration of clinical practice with regulatory documentation for pediatric procedures.
Disclaimer
The information in this article is for professional regulatory understanding only. It is not legal advice and does not replace counsel from regulatory or clinical ethics experts. Always refer to official regulatory guidance for current requirements.
For full information about the announcement see the link below.
https://clinicaltrials.gov/study/NCT07399041?term=medical+device